David Perlmutter

And there's a big, as of the time when you and I are sitting here right now, there's a big

confrontation, not just a debate, but a confrontation between neurologists and practitioners versus researchers saying, how should we diagnose Alzheimer's?

Is it based upon the blood markers or should we be really relying on how that patient is performing cognitively?

And I'm in the camp of the latter, along with the blood work and the brain scanning.

So you need all three?

My opinion, yes.

I don't want to start instituting treatments that are potentially harmful on people because they have, for example, high levels of beta amyloid.

There are plenty of patients who have high levels of this worrisome protein in their brains who do not go on to develop any clinical manifestations at all.

Why should we treat them?

Yeah, and of course, misdiagnosis, I think the idea of making the wrong diagnosis is an idea that I think is going to be vastly improved with AI.

I mean, I think ChatGPT is a heck of a lot smarter than I am.

And I'm- Wow, what a statement.

Yeah, well, no, I mean, it's reality.

I think when it comes to diagnosis, that's what we were talking about.

And I've always fancied myself as being really good at that.

I can walk into a room and make a diagnosis by looking at somebody and having a conversation.

And I've even made a diagnosis oftentimes in my office by smell.

We're way out there right now.

Yeah, I need to learn about that.

Well, that's something I don't really share a lot.